BIOMAT Database Logo BIOMAT Database Logo

Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. 1997

S L Clifford, and C P Kaminetsky, and F D Cirisano, and R Dodge, and J T Soper, and D L Clarke-Pearson, and A Berchuck
Department of Obstetrics and Gynecology/Division of Gynecologic Oncology, Duke University Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA.

OBJECTIVE This study was conducted to determine whether overexpression of the p53 tumor suppressor gene is associated with poor outcome in early-stage endometrial cancers and whether a racial difference in the frequency of p53 overexpression contributes to the observed racial disparity in survival rates. METHODS Immunostaining for the p53 gene was performed in 164 women with stage I endometrial adenocarcinomas. RESULTS Overexpression of mutant p53 protein was seen in 28 out of 164 (17%) cases and was associated with a poor histologic grade (p = 0.003) and a nonendometrioid histologic appearance (p = 0.06). Overexpression also was three times more frequent in blacks (15 out of 44, 34%) than in whites (13 out of 117, 11%) (p = 0.003). Recurrent disease developed in 15 out of 164 (9%) cases and was more than twice as frequent in cases when the p53 gene was overexpressed (5 out of 28, 18%) than in cases with normal expression (10 out of 136, 7%). Recurrent disease was seen in 6 out of 44 (14%) blacks compared to 9 out of 117 (8%) whites. CONCLUSIONS These data support the hypothesis that differences in the frequency of alteration of the p53 tumor suppressor gene contribute to the racial disparity in endometrial cancer survival.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D016158 Genes, p53 Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53. Genes, TP53,TP53 Genes,p53 Genes,Gene, TP53,Gene, p53,TP53 Gene,p53 Gene
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53

Related Publications

S L Clifford, and C P Kaminetsky, and F D Cirisano, and R Dodge, and J T Soper, and D L Clarke-Pearson, and A Berchuck
Overexpression of p53 tumor suppressor gene in pterygia.
September 2002, Eye (London, England),
S L Clifford, and C P Kaminetsky, and F D Cirisano, and R Dodge, and J T Soper, and D L Clarke-Pearson, and A Berchuck
P53 suppressor gene overexpression in oral cancer.
January 1997, Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal,
S L Clifford, and C P Kaminetsky, and F D Cirisano, and R Dodge, and J T Soper, and D L Clarke-Pearson, and A Berchuck
p53 protein overexpression in early stage endometrial cancer.
August 1996, Gynecologic oncology,
S L Clifford, and C P Kaminetsky, and F D Cirisano, and R Dodge, and J T Soper, and D L Clarke-Pearson, and A Berchuck
Overexpression of the tumor-suppressor gene p53 in human ovarian tumor-tissues and its correlation with clinical stage.
May 1994, International journal of oncology,
S L Clifford, and C P Kaminetsky, and F D Cirisano, and R Dodge, and J T Soper, and D L Clarke-Pearson, and A Berchuck
p53 overexpression in advanced-stage endometrial adenocarcinoma.
November 1996, American journal of obstetrics and gynecology,
S L Clifford, and C P Kaminetsky, and F D Cirisano, and R Dodge, and J T Soper, and D L Clarke-Pearson, and A Berchuck
The p53 tumor suppressor gene in breast cancer.
January 1994, Breast cancer research and treatment,
S L Clifford, and C P Kaminetsky, and F D Cirisano, and R Dodge, and J T Soper, and D L Clarke-Pearson, and A Berchuck
Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.
December 2001, Gynecologic oncology,
S L Clifford, and C P Kaminetsky, and F D Cirisano, and R Dodge, and J T Soper, and D L Clarke-Pearson, and A Berchuck
Racial disparity in the association of p53 gene alterations with breast cancer survival.
April 1995, Cancer research,
S L Clifford, and C P Kaminetsky, and F D Cirisano, and R Dodge, and J T Soper, and D L Clarke-Pearson, and A Berchuck
[The p53 tumor suppressor gene and ovarian cancer].
November 1995, Zhonghua fu chan ke za zhi,
S L Clifford, and C P Kaminetsky, and F D Cirisano, and R Dodge, and J T Soper, and D L Clarke-Pearson, and A Berchuck
P53 tumor suppressor gene therapy for cancer.
January 1998, Cancer gene therapy,
Copied contents to your clipboard!